- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00256035
Interleukin-4 (IL-4) as a Marker of Atherosclerosis
IL-4 as a Marker of Atherosclerosis
In recent years, medical research into the cause and progression of heart disease due to narrowing and blockage of blood vessels to the heart muscle has improved the understanding of ischemic heart disease. It is now accepted that both the development and later progression with sudden blockage of blood vessels are associated with inflammation, although it remains unknown exactly what triggers this inflammatory process. It is possible that new blood tests which measure markers of inflammation in the bloodstream may be useful to help identify patients at risk of heart damage and assess response to treatment.
The study plans to assess a new blood test for a known marker of inflammation (IL-4) in patients with heart disease.
The hypothesis of this study is that, the cytokine, IL-4, measured by a new assay, is abnormally elevated in the blood of patients with coronary artery disease.
Also hypothesized is that the degree of abnormality of blood IL-4, is related to important clinical events in such patients, including severity of disease, acute complications, and treatment.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a single centre, prospective, non randomised, non controlled, pilot study of the potential abnormality of a new test group of patients in whom the results are postulated to be abnormal.
The specific aims of the study are:
- To measure IL-4 by a new rapid on-site technique in patients with documented coronary artery disease presenting in a variety of acute clinical circumstances
- To evaluate any abnormal measurements in relation to the severity of the disease, acute vascular complication and newly prescribed medications.
It is proposed to study 4 small groups of patients with ischemic heart disease.
- Patients with unstable coronary artery disease admitted to the Coronary Care Unit. They will be studied on admission and then daily until coronary angiography is performed.
- Patients having coronary angioplasty. They will be studied before, immediately after and 24 hours after the procedure.
- Patients having coronary artery bypass grafting will be studied immediately after and 24 hours post surgery.
- Patients with stable coronary artery disease about to receive a statin and or angiotensin-converting enzyme inhibitor therapy will be studied before and twice weekly after commencement of therapy for 4 weeks.
Study Type
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- All patients (either sex and any age) presenting in the settings described will be eligible to participate.
Exclusion Criteria:
- An unwillingness to participate.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Unstable coronary artery disease
Patients with unstable coronary artery disease will have daily IL6 levels
|
|
Other: Coronary Angioplasty Patients
Patients having coronary angioplasty will have levels taken before and immediately after the proceedure and 24 hours post.
|
|
Other: Coronary bypass grafts patients
Patients will have levels collected immediately after and 24 hours post procedure
|
|
Other: Stable coronary Artery Diseaese Patients
Once the patients are commenced on treatment with statins and or angiotensin converting enzyme they will have twice weekly levels taken
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To measure the IL-4 by a new rapid point-of-care technique in patients with documented coronary artery disease presenting in a variety of acute clinical circumstances
Time Frame: Hospital Discharge
|
Hospital Discharge
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To evaluate any abnormal measurements in relation to the severity of the disease, acute vascular complications, and newly prescribed medications
Time Frame: Hospital Discharge
|
Hospital Discharge
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Megan Robertson, Melbourne Health
Study record dates
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2002.156
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atherosclerosis
-
University Hospital, CaenUnknownPeripheral Arterial Disease | Atherosclerosis Obliterans | Atherosclerosis Right Leg | Atherosclerosis Left LegFrance
-
Nantes University HospitalAbbottCompletedAtherosclerosis ObliteransFrance
-
Central Hospital, Nancy, FranceSuspended
-
Federal University of São PauloCompletedAtherosclerosis of ArteryBrazil
-
MedtronicActive, not recruitingAtherosclerosis of Femoral Artery | Obstructive Disease | Atherosclerosis of Popliteal ArteryFrance
-
Cabinet de Medecine Interne Générale Demetrio PitarchCompletedAtherosclerosis of Artery
-
Emory UniversityThe Robert W. Woodruff FoundationCompleted
-
Korea UniversityMinistry of Health & Welfare, KoreaCompletedAtherosclerosis | Noninvasive Imaging of AtherosclerosisKorea, Republic of
-
Zhejiang Zylox Medical Device Co., Ltd.RecruitingAtherosclerosis of Femoral ArteryGermany
-
VA Office of Research and DevelopmentCompletedSaphenous Vein Graft AtherosclerosisUnited States
Clinical Trials on Measuring IL-4 levels
-
Aalborg University HospitalAalborg UniversityNot yet recruitingArthroplasty, Replacement, Knee
-
Sohag UniversityRecruitingAcute Gastroenteritis | Acute DiarrheaEgypt
-
Sohag UniversityRecruitingAcute Gastroenteritis | Severe Acute Malnutrition | Acute DiarrheaEgypt
-
University of MessinaCompleted
-
Osijek University HospitalRecruitingSystemic Inflammatory Response Syndrome | Postoperative Complications | Surgery | Obesity, AbdominalCroatia
-
Sohag UniversityNot yet recruiting
-
Vanderbilt University Medical CenterAmerican Heart AssociationRecruitingLong COVID | SARS CoV 2 Infection | Post-acute COVID-19 Syndrome | Postural Tachycardia Syndrome (POTS)United States
-
Alvine Pharmaceuticals Inc.Completed
-
Duke UniversityNational Institute of Allergy and Infectious Diseases (NIAID); Moi University; Clinton Health Access Initiative, NigeriaCompletedMalaria | Febrile IllnessKenya
-
Astellas Pharma Europe B.V.CompletedPharmacokinetics of ASP1707 | Pharmacodynamics of ASP1707France